| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 5. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | fluticasone propionate/formoterol fumarate (Flutiform K-Haler®) |
| Formulation | 50 micrograms/5 micrograms, 125 micrograms/ 5 micrograms and 250 micrograms/10 micrograms metered dose inhaler |
| Reference number | 2825 |
| Indication | Regular treatment of asthma in adults and adolescents over 12 years where the use of a combination product (an inhaled corticosteroid and a long-acting β2 agonist) is appropriate: For patients not adequately controlled with inhaled corticosteroids and 'as required' inhaled short-acting β2 agonist, or for patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist |
| Company | Napp Pharmaceuticals Ltd |
| BNF chapter | Respiratory system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 07/02/2018 |